Researchers say the U.K.’s NHS could save $8B by adopting new diagnostic tests

London Tower Bridge
Researchers say new diagnostic tests could help the U.K.’s National Health Service save more than $8 billion in five years. (Getty Images/Moussa810

Researchers say that by quickly adopting new diagnostic tests, the U.K.’s National Health Service could save more than $8 billion (£6.9 billion) over the next five years.

The research—commissioned by Innovate UK and the British in Vitro Diagnostics Association—said the benefits from adopting three new tests targeted at heart attacks, pre-eclampsia and inflammatory bowel disease would reduce unnecessary procedures and medication while also helping the NHS trim what is expected to be a shortfall of $23.2 billion (£20 billion) by 2022.

The report wants healthcare leaders and policymakers to take a look at the three high-impact diagnostics, along with many others currently available, and how they could be used within the NHS.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"There are so many innovative diagnostic tests on the market and in development,” Kath Mackay, Innovate UK‘s Interim Director for Aging Society, Health & Nutrition, said in a statement. “It's important for all stakeholders that we take every opportunity to rapidly adopt tests which show cost savings and benefit to patients."

Last year, the NHS announced it was scaling up a program to detect lung cancer earlier and also unveiled a new test to catch bowel cancer. That decision was based on the success of the Manchester scanning program that used mobile scanners to detect 4 out of 5 cases of lung cancer in the early stages. The mobile scanning trucks were able to find one cancer for every 33 patients scanned over the course of a year.

The service also said it would begin using FIT, a more sensitive bowel cancer test that is expected to catch as many as 1,500 more cancer cases in their early stages each year.

Suggested Articles

Profusa's latest offering provides doctors a “broader data picture” and offers patients a more convenient way to check oxygen levels in their limbs.

Digital stethoscope company Eko has received FDA clearance for its AI algorithms to help detect asymptomatic heart conditions.

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.